Abstract:Many recent studies have shown that flagellin fused to heterologous antigens can induce significantly enhanced humoral and cellular immune responses through its adjuvant activity. Therefore, in this study, two key B cell epitopes and a truncated VP1 (ΔVP1) protein from foot-and-mouth disease virus (FMDV) were expressed as flagellin fusion proteins in different patterns. Specifically, ΔVP1 and two duplicates of two key B cell epitopes (2×B1B2) were fused separately to the C-terminus of flagellin with a universal exogenous T cell epitope to construct FT (Flagellin-Truncated VP1) and FME (Flagellin-Multiple Epitopes). In addition, the D3 domain of flagellin was replaced by ΔVP1 in FME, yielding FTME (Flagellin-Truncated VP1-Multiple Epitopes). The immunogenicity and protective efficacy of the three fusion proteins as novel FMDV vaccine candidates were evaluated. The results showed that FT, FME, and FTME elicited significant FMDV-specific IgG responses at 10 μg/dose compared with the mock group (P < 0.05), with FTME producing the highest response. No significant differences in the antibody response to FTME were observed between different immunization routes or among adjuvants (ISA-206, poly(I·C), MPLA, and CpG-ODN) in mice. In addition, at 30 μg/dose, all three fusion proteins significantly induced neutralizing antibody production and upregulated the levels of some cytokines, including TNF-α, IFN-γ, and IL-12, in guinea pigs. Importantly, all three fusion proteins provided effective protective immunity against FMDV challenge in guinea pigs, though different protection rates were found. The results presented in this study indicate that the FTME fusion protein is a promising novel vaccine candidate for the future prevention and control of foot-and-mouth disease.

Immunogenicity analysis of the E. coli expressed structural protein VP1 of persistent infection foot-and-mouth disease virus

Prokaryotic Expression of Structural Protein VP1 of Foot-and-mouth disease virus Type O and Analysis of Its Antigenicity

Development of Tobacco necrosis virus A as a vector for efficient and stable expression of FMDV VP1 peptides.

Prokaryotic Expression and Activity Analysis of VP1 Gene of Foot-and-Mouth Disease Virus Serotype O

Prokaryotic Expression and Activity Analysis of VP1 of Foot-and-Mouth Disease Virus Serotype A

A Novel Mucosal Vaccine Against Foot-and-Mouth Disease Virus Induces Protection in Mice and Swine

Development of recombinant vp1 protein immunised in mice as a model of foot-and-mouth disease vaccine

Antigenicity and Immunogenicity Analysis of the E. coli Expressed FMDV Structural Proteins; VP1, VP0, VP3 of the South African Territories Type 2 Virus

Potent immune responses against thermostable Foot-and-Mouth disease virus VP1 nanovaccine adjuvanted with polymeric thermostable scaffold

Expression and Immunogenicity of Two Recombinant Fusion Proteins Comprising Foot-and-Mouth Disease Virus Structural Protein VP1 and DC-SIGN-Binding Glycoproteins

Detection of Foot-and-mouth Virus Antibodies Using a Purified Protein from the High-Level Expression of Codon-Optimized, Foot-and-mouth Disease Virus Complex Epitopes in Escherichia Coli.

Development of an Indirect ELISA Based on VP1-CRT Fusion Protein for Detection of FMDV-O in Swine

B cell epitopes within VP1 of type O foot-and-mouth disease virus for detection of viral antibodies

High-level expression of codon optimized foot-and-mouth disease virus complex epitopes and cholera toxin B subunit chimera in Hansenula polymorpha.

Immunogenicity and protective efficacy of recombinant proteins consisting of multiple epitopes of foot-and-mouth disease virus fused with flagellin

Soluble Expression and Immuneoreactivity Analysis of FMDV VP0 and VP1 Protein

The immune response to a recombinant Lactococcus lactis oral vaccine against foot-and-mouth disease virus in mice

Expression of the VP1 protein of FMDV integrated chromosomally with mutant Listeria monocytogenes strain induced both humoral and cellular immune responses

Soluble FMDV VP1 Proteins Fused with Calreticulin Expressed in Escherichia Coli under the Assist of Trigger Factor16 (tf16) Formed into High Immunogenic Polymers.

Immunogenicity of Recombinant Fowl-Pox Virus Co-Expressing Structural Protein Precursor P1-2A and Proteinase 3C of FMDV

A novel immunoinformatics approach for developing a poly-epitope vaccine targeting foot and mouth disease virus, exploiting structural VP proteins